Delta Manuf Peer Comparison
NSE: DELTAMAGNT | BSE: 504286
₹55.03
As on 09-Oct-2026IST
Market cap
₹60 Cr
Revenue (TTM)
₹67 Cr
P/E Ratio
--
P/B Ratio
24.3
Div. Yield
0 %
| Delta Manuf | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
60 | 9,841 | 297 | 215 | 42 |
Revenue (₹ Cr) |
67 | 23,506 | 82 | 434 | 181 |
Net Profit (₹ Cr) |
-7.30 | 553.62 | 10.62 | 17.44 | 2.66 |
Net Margin (%) |
0.51 | 2.35 | 12.59 | 3.90 | 1.42 |
RoE (%) |
-47.21 | 10.18 | 9.30 | 6.80 | 2.82 |
Price to Earnings |
-- | 17.78 | 27.98 | 12.34 | 19.85 |
Price-To-Book |
24.30 | 1.58 | 2.39 | 0.83 | 0.57 |
Income Statement (₹ Cr)
| Delta Manuf | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Operating Revenue
|
61.87 | 23,505.54 | 80.43 | 430.87 | 130.23 |
|
Total Income
|
63.37 | 23,662.81 | 83.18 | 442.48 | 133.35 |
|
Total Expenditure
|
57.54 | 21,745.77 | 64.21 | 407.51 | 123.85 |
|
EBITDA
|
4.33 | 1,759.77 | 16.22 | 23.37 | 6.38 |
|
Depreciation
|
2.76 | 197.38 | 4.38 | 10.92 | 3.37 |
|
EBIT
|
1.57 | 1,562.39 | 11.84 | 12.45 | 3.01 |
|
Interest
|
0.79 | 871.74 | 0.56 | 12.97 | 11.88 |
|
Other Income
|
1.50 | 157.27 | 2.75 | 11.60 | 3.13 |
|
Exceptional Items
|
0.09 | -58.78 | -0.60 | 11.95 | -- |
|
Profit before Tax
|
-0.99 | 789.14 | 13.44 | 11.08 | -5.74 |
|
Provision for Tax
|
0.08 | 183.55 | 3.63 | 1.61 | 0.36 |
|
Profit after Tax
|
-1.06 | 605.59 | 9.81 | 9.47 | -6.11 |
Liabilities (₹ Cr)
| Delta Manuf | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2.31 | 6,159.69 | 122.45 | 257.94 | 72.51 |
|
Minority Interest
|
-- | -- | -- | -- | 27.41 |
|
Non-Current Liabilities
|
8.14 | 515.16 | 2.31 | 68.01 | 65.54 |
|
Current Liabilities
|
55.00 | 18,007.82 | 9.40 | 236.55 | 102.48 |
|
Total Liabilities
|
68.45 | 25,133.45 | 134.69 | 567.57 | 267.94 |
Assets (₹ Cr)
| Delta Manuf | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
39.29 | 2,473.59 | 75.09 | 313.41 | 90.00 |
|
Current Assets
|
26.27 | 22,209.08 | 59.07 | 249.09 | 177.94 |
|
Total Assets
|
68.45 | 25,133.45 | 134.69 | 567.57 | 267.94 |
|
Total Debt*
|
39.12 | 5,103.23 | 2.43 | 148.60 | 137.07 |
|
Net Current Assets
|
-28.73 | 4,201.26 | 49.67 | 12.55 | 75.45 |
|
Contingent Liabilities
|
4.61 | 188.22 | 2.67 | 16.95 | -- |
Cashflow (₹ Cr)
| Delta Manuf | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
0.66 | -414.12 | 12.08 | 14.25 | -6.74 |
|
Cash Flow from Investing Activities
|
-9.76 | -241.80 | -10.09 | -8.24 | 24.74 |
|
Cash from Financing Activities
|
9.44 | 510.97 | -5.36 | -3.75 | -18.30 |
|
Net Cash Inflow / Outflow
|
0.34 | -144.95 | -3.37 | 2.26 | -0.29 |
Ratios
Profitability Ratios
| Delta Manuf | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-0.48 | 16.35 | 11.43 | 6.08 | 3.19 |
|
ROE (%)
|
-12.57 | 10.53 | 8.31 | 3.76 | -9.25 |
|
ROA (%)
|
-1.56 | 2.61 | 7.52 | 1.74 | -2.44 |
|
EBIT Margin (%)
|
9.42 | 8.16 | 23.59 | 8.12 | 7.30 |
|
Net Margin (%)
|
-1.68 | 2.56 | 11.79 | 2.14 | -4.58 |
|
Cash Profit Margin (%)
|
2.75 | 3.42 | 17.64 | 4.72 | -2.10 |
Growth Ratios
| Delta Manuf | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
10.80 | 7.59 | 16.72 | -2.78 | -21.66 |
|
EBIT Growth (%)
|
33.58 | 9.54 | 18.11 | -3.51 | -61.80 |
|
Net Profit Growth (%)
|
-250.62 | 6.11 | 27.10 | -64.58 | -158.60 |
|
EPS Growth (%)
|
-2.64 | 6.11 | 27.10 | -64.58 | -124.45 |
|
Book Value Growth (%)
|
-84.21 | 15.19 | 7.79 | 5.20 | 9.39 |
Valuation Ratios
| Delta Manuf | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 22.49 | 13.36 | 18.22 | 0.00 |
|
Price / Book Value
|
21.65 | 2.21 | 1.07 | 0.67 | 0.94 |
|
Dividend Yield (%)
|
0.00 | 1.08 | 0.91 | 0.00 | 0.00 |
|
EV/EBITDA
|
15.18 | 9.50 | 6.00 | 9.09 | 21.23 |
|
Market Cap (₹ Cr)
|
49.91 | 13,619.11 | 131.05 | 172.48 | 64.93 |
Solvency Ratios
| Delta Manuf | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Debt to Equity
|
16.97 | 0.83 | 0.02 | 0.58 | 1.99 |
|
Short term debt to equity ratio
|
14.97 | 0.68 | 0.03 | 0.41 | 0.97 |
|
Current Ratio
|
0.48 | 1.23 | 6.28 | 1.05 | 1.74 |
|
Quick Ratio
|
0.33 | 1.15 | 4.84 | 0.60 | 1.33 |
|
Interest Coverage
|
-0.25 | 1.91 | 25.20 | 1.85 | 0.52 |
Operating Efficiency Ratios
| Delta Manuf | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
19.80 | 27.54 | 27.55 | 14.66 | 45.07 |
|
Asset Turnover
|
0.91 | 1.01 | 0.62 | 0.80 | 0.52 |
|
Receivable days
|
79.88 | 89.48 | 87.30 | 52.78 | 137.64 |
|
Inventory Days
|
57.53 | 20.76 | 61.62 | 83.71 | 117.29 |
|
Payable days
|
149.50 | 238.84 | 135.35 | 179.84 | 134.44 |
|
Cash Conversion Cycle
|
-12.09 | -128.60 | 13.57 | -43.36 | 120.49 |